Why and when reexams can be a better option than inter partes reviews at the USPTO

Why and when reexams can be a better option than inter partes reviews at the USPTO

The long read: There is growing evidence that patent litigants are turning to ex parte reexaminations to bolster their PTAB strategies. Cozen O’Connor’s Jeffrey Townes and Hongling Zou analyse why older tools deserve a second look and explore how to get best value from them

Unlock unlimited access to all IAM content